Clinical trials · Baltimore, MD
Non Small Cell Lung Cancer Metastatic clinical trials in Baltimore
We’re tracking 92 recruiting non small cell lung cancer metastatic studies with a site in or near Baltimore — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Baltimore
- NCT06767514RecruitingPhase 3
Ivonescimab for first-line treatment of advanced NSCLC with high PD-L1
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
Baltimore, MarylandAges 18 years+ - NCT07223047RecruitingPhase 1/Phase 2
Study of BMS-986523 for advanced solid tumors with KRAS changes
This trial tests an experimental drug (BMS-986523) alone or with other cancer treatments for people with advanced solid tumors that have a specific change in the KRAS gene. It aims to see if the drug is safe and effective.
Baltimore, MarylandAges 18 years+ - NCT06500481RecruitingPhase 3
Proton vs standard radiation for cancer spread to brain/spine lining
This trial compares a newer type of radiation (proton therapy) to standard radiation for people whose breast or lung cancer has spread to the lining of the brain and spinal cord. It aims to see if proton therapy can better control the disease while causing fewer side effects.
Baltimore, MarylandAges 18 years+ - NCT07680764RecruitingPhase 2
Imzokitug plus pumitamig and chemo for first-line advanced lung cancer
This trial tests a new combination of drugs (imzokitug, pumitamig, and platinum-doublet chemotherapy) as a first treatment for advanced or metastatic non-small cell lung cancer that has not spread to the brain. The goal is to see if adding imzokitug makes the standard treatment work better.
Baltimore, MarylandAges 18 years+ - NCT06064877RecruitingPhase 3
Study of ficlatuzumab plus cetuximab for advanced head and neck cancer
This trial tests a combination of two drugs, ficlatuzumab and cetuximab, for people with recurrent or metastatic head and neck cancer that is HPV-negative and has not responded to prior immunotherapy and chemotherapy. It aims to see if this combination can help shrink tumors or slow the disease.
Baltimore, MarylandAges 18 years+ - NCT06131840RecruitingPhase 1
Study of SGN-CEACAM5C for advanced solid tumors
This trial tests a new drug called SGN-CEACAM5C in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein on cancer cells to try to stop them from growing.
Baltimore, MarylandAges 18 years+ - NCT02984761Recruiting
Surgery vs focused radiation for early lung cancer
This trial compares two ways to treat early-stage lung cancer: surgery or a precise type of radiation called stereotactic radiotherapy. It aims to find out which approach works best for people whose cancer is small and has not spread.
Baltimore, MarylandAges 18 years+ - NCT06627647RecruitingPhase 3
Comparing two immunotherapy drugs for advanced lung cancer
This trial tests a new immunotherapy drug, rilvegostomig, against the standard pembrolizumab, both given with chemotherapy, as a first treatment for advanced non-squamous non-small cell lung cancer (NSCLC) that cannot be cured with surgery or radiation. It is for people whose tumors have high PD-L1 levels and do not have certain genetic mutations.
Baltimore, MarylandAges 18 years+ - NCT06472245RecruitingPhase 3
Cancer vaccine for lung cancer that stopped responding to immunotherapy
This trial tests a therapeutic cancer vaccine called OSE2101 for people with advanced non-small cell lung cancer whose tumors stopped responding to an immunotherapy drug. The vaccine is designed to help your immune system fight the cancer in a different way.
Baltimore, MarylandAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Baltimore, MarylandAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Baltimore, MarylandAges 18 years+ - NCT07291037RecruitingPhase 3
Study of datopotamab deruxtecan vs docetaxel for advanced lung cancer
This trial tests a new drug, datopotamab deruxtecan, against a standard chemotherapy (docetaxel) for people with advanced non-squamous lung cancer that has gotten worse after previous treatment. It is for those who do not have certain genetic changes (like EGFR, ALK, or ROS1) and whose tumors have a protein called TROP2.
Baltimore, MarylandAges 18 years+ - NCT07154290RecruitingPhase 2
Ubamatamab with or without REGN7075 for advanced lung cancer
This trial tests a new targeted therapy (ubamatamab) alone or with another drug (REGN7075) for people with advanced or metastatic non-small cell lung cancer that has gotten worse after standard treatment. It aims to see if targeting MUC16, a substance found on some cancer cells, can help control the cancer.
Baltimore, MarylandAges 18 years+ - NCT07349537RecruitingPhase 1
Study of RMC-5127 for advanced KRAS G12V-mutant solid tumors
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
Baltimore, MarylandAges 18 years+ - NCT06500455RecruitingPhase 3
Standard vs longer radiation for brain metastases
This trial compares the usual short course of radiation therapy (one session) to a longer course (up to 5 sessions) for people with cancer that has spread to the brain. The goal is to see if the longer course works better and causes fewer side effects.
Baltimore, MarylandAges 18 years+ - NCT05142189RecruitingPhase 1
Testing BNT116 for advanced non-small cell lung cancer
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
Baltimore, MarylandAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Baltimore, MarylandAges 18 years+ - NCT06417814RecruitingPhase 3
Study of Dato-DXd with or without osimertinib for EGFR-mutated lung cancer
This trial tests a new drug, Dato-DXd, given alone or with osimertinib, versus standard chemotherapy for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) that has worsened after osimertinib treatment.
Baltimore, MarylandAges 18–130 - NCT06800339RecruitingPhase 1
Immunotherapy and radiation before surgery for lung cancer
This trial tests combining chemotherapy, immunotherapy, and a low dose of radiation before surgery for people with non-small cell lung cancer that is borderline resectable (can potentially be removed but is close to nearby structures). It aims to see if this approach can shrink the tumor enough to allow successful surgery.
Baltimore, MarylandAges 18 years+ - NCT06996782RecruitingPhase 1/Phase 2
Lung cancer study testing new combination treatments
This study tests a new drug (rilvegostomig) alone or with chemotherapy or another drug (ramucirumab) for advanced non-small cell lung cancer that has spread. It aims to see if these combinations work better than standard treatments.
Baltimore, MarylandAges 18 years+ - NCT04410796RecruitingPhase 2
Osimertinib alone or with chemo for EGFR-mutant lung cancer
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
Baltimore, MarylandAges 18 years+ - NCT05585684Recruiting
Blood test to guide next cancer treatment choices
This study checks whether a blood test can find tumor genetic changes (called “plasma genomic profiling”) to help choose the best next treatment. It may help your care team decide therapy after your cancer progresses or seems likely to progress soon.
Baltimore, MarylandAges 18 years+ - NCT04614103RecruitingPhase 2
Immune cell therapy for advanced lung cancer after chemotherapy
This trial studies LN-145, a treatment made from your own immune cells, for metastatic (stage IV) non-small-cell lung cancer. It may help shrink tumors after your cancer has progressed despite standard first-line chemotherapy and immunotherapy.
Baltimore, MarylandAges 18–70 - NCT07020221RecruitingPhase 1/Phase 2
Study of VS-7375 for KRAS G12D solid tumors
This trial tests a new oral drug called VS-7375 for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if it can shrink tumors or slow their growth.
Baltimore, MarylandAges 18 years+
Hear when a new Non Small Cell Lung Cancer Metastatic trial opens near Baltimore, MD
We’ll email you when one opens near Baltimore, MD — at most once a week, no account needed, unsubscribe anytime.
Non Small Cell Lung Cancer Metastatic trials in other cities
Where these studies are running near Baltimore
Institutions with a site for the recruiting non small cell lung cancer metastatic studies listed above.
- Johns Hopkins University · 5 studies
- Research Site · 4 studies
- University of Maryland · 3 studies
- University of Maryland Greenebaum Comprehensive Cancer Center · 3 studies
- Children's National Medical Center · 2 studies
- Georgetown University Medical Center · 2 studies
- Maryland Proton Treatment Center · 2 studies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 2 studies
What taking part in a non small cell lung cancer metastatic study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting non small cell lung cancer metastatic studies in Maryland.
Common questions
- Are there non small cell lung cancer metastatic clinical trials near Baltimore?
- Yes. We're currently tracking 92 recruiting non small cell lung cancer metastatic studies with a site near Baltimore, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a non small cell lung cancer metastatic study near Baltimore?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Baltimore to take part?
- Not necessarily. These studies have a site near Baltimore, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a non small cell lung cancer metastatic trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New non small cell lung cancer metastatic studies open near Baltimore regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.